ForSight Vision5, an early-stage ophthalmology company based in Silicon Valley, named venture capitalist and medtech veteran John Maroney as its new chief executive.
The Menlo Park, Calif.-based company, which is focused on developing technologies for the ophthalmic market, said Maroney will serve as president, CEO and a director of the firm. He previously held positions at EndoTex Interventional Systems, which was bought by Boston Scientific (NYSE:BSX) in 2007, and currently serves as a general partner at Delphi Ventures.
The company also said it closed a$9.3 million Series B-1 round led by Technology Partners of Palo Alto. Maroney’s Delphi Ventures also participated in the round.
ForSight Vision5 is spinout of ForSight Labs, a Menlo Park-based incubator focused on "developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients," according to its website.